Stockholm’s Brakket Invest Picks Up MENA-Based Tech Firm
6.10.2021 11:00:00 EEST | Business Wire | Press release
Brakket Invest, a growth equity fund based in Stockholm and Dubai, signed an agreement this week to acquire BEON-IT, a SAP Gold-Partner firm with offices throughout the Middle East. The move will give Brakket Invest a foothold in the global tech industry as it gears up to launch its operations in Switzerland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211006005013/en/
Stockholm’s Brakket Invest Picks Up MENA-Based Tech Firm (Photo: Business Wire)
“This acquisition confirms our commitment to fueling the growth of tech pioneers, especially in the GCC and DACH regions, where demand for SAP solutions continues to grow exponentially,” Brakket Group Managing Partner M. Hussein El Hakim says.
SAP is widely recognized as the global leader in enterprise software for the management of business operations.
BEON-IT: Digitalizing the Region’s SMEs
On October 6, 2020 a Big Four firm announced its acquisition of Tyconz Enterprise Business to expand its Technology and Digital Consulting Business. Tyconz’ SME business was excluded from the acquisition, and was later rebranded as Beon-IT.
With six offices across the region and a qualified team of over 50 Arabic-speaking experts, BEON-IT has served more than 200 blue-chip companies across the region, in a variety of industries like EC&O, manufacturing, retail, professional services and consumer goods.
Beon-IT CEO Shadi Abdelkhalek voiced his pleasure with the acquisition, which, he explained, would allow BEON-IT to achieve its full market potential. “We’re thrilled that the organization will be joining Brakket Invest, and are confident that the move will help it expand into new markets and offer its clients more innovative services,” he says.
Leveraging Booming Potential
With BEON-IT having been advised by Awad Capital Ltd., a DFSA regulated firm, and Brakket Invest’s expansive presence across the EMEA region, the new partnership abounds with growth potential. BEON-IT will now enjoy access to Brakket’s extensive SAP consulting expertise, diverse network of partners, and consolidated advisory resources.
“We’re particularly well-positioned to help BEON-IT realize its latent potential,” Brakket Invest’s el Hakim says. “This acquisition will enable us to solidify our tech capabilities as we join forces in the digital transformation of the region’s SMEs.”
Brakket Invest is a Dubai & Stockholm-based growth equity fund that invests in high-growth, high-potential ventures in deep-tech, Internet and consumer platforms, shaping & transforming them into tomorrow’s regional market leaders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211006005013/en/
Contact information
M. Hussein el Hakim
+971 – 4313 2599
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom